This is Part I of our special report on the state of immunotherapy in the public markets. This report looks at promising anticancer immunotherapy technologies, and the major issues in bringing these technologies to the general public.
Smart Stocks Watch: Apricus Bio — Erectile Dysfunction, Anti-Fungals
The San Diego-based pharmaceutical company has five approved products internationally, covering erectile dysfunction (Vitaros), side effects of cancer therapy (Totect and Granisol), coronary artery disease (Nitromist) and dry mouth (Aquoral). After a series of successes in strategic partnerships, acquisitions, peer review and clinical data in Q3, the company is garnering some serious attention.
OneMedRadio: ADVENTRX Hosts First Annual Sickle Cell Disease Therapeutics Conference
September is Sickle Cell Awareness Month, a time when the medical community will gather with the patient population in the hopes of advancing research in this significant unmet medical need. One company, ADVENTRX Pharmaceuticals [NYSE: ANX], is attempting to engage the investor community and the sector’s most promising drug developers through the First Annual Sickle Cell Disease Therapeutics Conference, taking place September 19th, 2012 in New York City.
Editor’s Note September 18, 2012
With the end of summer, conference season is upon us! Not OneMedForum, of course, which doesn’t kick off until “Biotech Week” in mid-January. But in New York, investors gathered for the autumn […]
Your Biotech Calendar, August 28: PDUFA Dates, SEC Filings, Financings
At OneMedPlace, our goal is to be your eyes and ears to the biotech and life sciences sector: putting into perspective what we’ve seen so far, and providing you with snapshots of and what’s upcoming.
OneMedRadio: Dr. Daniel Teper of Immune Pharmaceuticals on the Power of Monoclonal Antibodies
IMMUNE Pharmaceuticals is an Israeli and US based emerging leader in the development of antibody therapeutics in cancer and inflammation. IMMUNE has multiple drug candidates based on proprietary cytotoxic formulations, linkers and monoclonal antibodies.
Zymeworks Invited to Present AntiBody Technology at OneMedForum NY 2012
Zymeworks Inc. is a privately held biotechnology company committed to developing best-in-class protein therapeutics for the treatment of cancer.
Editor’s Note June 5, 2012
This week, we respond to a recent Wall Street Journal article documenting immunotherapy as a new treatment for Cancer. We tell you what companies they missed. OneMedRadio brings you management interviews with […]
